CULLINAN THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
CULLINAN THERAPEUTICS INC. - More news...
CULLINAN THERAPEUTICS INC. - More news...
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
- Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
- Cullinan Oncology to Participate in Upcoming Investor Conferences
- Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
- Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
- Cullinan Oncology to Participate in Upcoming Investor Conferences
- Cullinan Oncology to Participate in Upcoming Investor Conferences
- Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Cullinan Oncology to Participate in Upcoming Investor Conferences
- Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
- Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
- Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
- Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
- Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
- Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
- Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
- Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)